Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:36 PM
Ignite Modification Date:
2025-12-24 @ 4:36 PM
NCT ID:
NCT05427266
Eligibility Criteria:
Inclusion Criteria:
* Provide signed and dated informed consent form
* Willing to comply with all study procedures and be available for follow up telephone follow up
* Male or female, aged over 18
* Diagnosed either clinically or radiologically (CT/US/MRI) with appendicitis
* Uncomplicated or complicated appendicitis
* Undergoing laparoscopic appendicitis surgery only
* Must be fluent in English in order to complete telephone follow up questionnaire
* Fulfillment of each criteria must be clearly evidenced (in lab reports or correspondence) and/or documented in the medical records.
Exclusion Criteria:
* Male or female under the age or 18
* Laparoscopic converted to open appendicectomy (during surgical procedure)
* Open appendicectomy (planned)
* Pregnancy.
* Females must not be breastfeeding
* Known allergic reactions to components of the study product(s) )
* Not fluent in English - which would prevent participants to complete follow up telephone questionnaire
* Malignant appendicitis
* Spinal Anaesthesia, Epidural analgesia catheter or injections, Post-operative requirements for patient controlled analgesia (PCA)
* Right hemicolectomy or any concomitant or simultaneous intervention
* Allergy or hypersensitivity to any of the components of Bupivacaine
* Presence of any other illness or condition that renders the patient unsuitable for trial participation in the opinion of the investigator
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05427266
Study Brief:
Protocol Section:
NCT05427266